BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37776771)

  • 1. PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR/STAT-3/ROR-γt pathway.
    Yu M; Tang W; Liang W; Xie B; Gao R; Ding P; Gu X; Wang M; Wen S; Sun P
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110962. PubMed ID: 37776771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis.
    Yamashita T; Iwakura T; Matsui K; Kawaguchi H; Obana M; Hayama A; Maeda M; Izumi Y; Komuro I; Ohsugi Y; Fujimoto M; Naka T; Kishimoto T; Nakayama H; Fujio Y
    Cardiovasc Res; 2011 Sep; 91(4):640-8. PubMed ID: 21622681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice.
    Tajiri K; Shimojo N; Sakai S; Machino-Ohtsuka T; Imanaka-Yoshida K; Hiroe M; Tsujimura Y; Kimura T; Sato A; Yasutomi Y; Aonuma K
    Cardiovasc Drugs Ther; 2013 Oct; 27(5):413-24. PubMed ID: 23722419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARα suppresses Th17 cell differentiation through IL-6/STAT3/RORγt pathway in experimental autoimmune myocarditis.
    Chang H; Zhao F; Xie X; Liao Y; Song Y; Liu C; Wu Y; Wang Y; Liu D; Wang Y; Zou J; Qi Z
    Exp Cell Res; 2019 Feb; 375(1):22-30. PubMed ID: 30557558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response.
    Yan L; Hu F; Yan X; Wei Y; Ma W; Wang Y; Lu S; Wang Z
    J Mol Med (Berl); 2016 Sep; 94(9):1063-79. PubMed ID: 27052830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of phosphoglycerate kinase 1 attenuates autoimmune myocarditis by reprogramming CD4+ T cell metabolism.
    Lu Y; Zhao N; Wu Y; Yang S; Wu Q; Dong Q; Du Y
    Cardiovasc Res; 2023 Jun; 119(6):1377-1389. PubMed ID: 36726197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The protective role of interleukin-6 monoclonal antibody on experimental autoimmune myocarditis and its mechanism].
    He S; Han LN; Wang YT; Liu JW; Ding GL
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Mar; 30(2):119-23. PubMed ID: 25016860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 promotes T helper 1 and T helper 17 cell differentiation by activating the nuclear factor-κB pathway in ankylosing spondylitis.
    Cai J; Jiang Y; Chen F; Wu S; Ren H; Wang P; Wang J; Liu W
    Immun Inflamm Dis; 2023 May; 11(5):e870. PubMed ID: 37249282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis.
    Ohshima M; Yamahara K; Ishikane S; Harada K; Tsuda H; Otani K; Taguchi A; Miyazato M; Katsuragi S; Yoshimatsu J; Kodama M; Kangawa K; Ikeda T
    J Mol Cell Cardiol; 2012 Sep; 53(3):420-8. PubMed ID: 22796574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating PCSK9 relates to aggravated disease activity, Th17/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients.
    Meng Y; Zheng X; Zhang Z; Geng H; Li X
    Ir J Med Sci; 2023 Dec; 192(6):3187-3194. PubMed ID: 36826711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
    Venugopal J; Wang J; Guo C; Lu H; Chen YE; Eitzman DT
    Sci Rep; 2020 Oct; 10(1):16514. PubMed ID: 33020528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saikosaponin A ameliorates nasal inflammation by suppressing IL-6/ROR-γt/STAT3/IL-17/NF-κB pathway in OVA-induced allergic rhinitis.
    Piao CH; Song CH; Lee EJ; Chai OH
    Chem Biol Interact; 2020 Jan; 315():108874. PubMed ID: 31669322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
    Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
    Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9.
    Leung AKK; Xue YC; de Guzman A; Grzelkovski G; Kong HJ; Genga KR; Russell JA; Boyd JH; Francis GA; Walley KR
    Atherosclerosis; 2022 Dec; 362():29-37. PubMed ID: 36207148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.
    Li W; Zhang Z; Zhang K; Xue Z; Li Y; Zhang Z; Zhang L; Gu C; Zhang Q; Hao J; Da Y; Yao Z; Kong Y; Zhang R
    Mol Neurobiol; 2016 Oct; 53(8):5356-66. PubMed ID: 26440666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
    Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.